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The maximum displacement in mm had no influence on acute 
GI toxicity (p=0.63) nor acute GU toxicity (p=0.73). 
For both acute GI (p=0.36) and GU (p=0.56) toxicity the 
number of displacements was not statistically significant. 
No statistically significant differences were seen in late GI 
toxicity between NDP (9.4%) and DP (8.6%) (p=1.0), while late 
GU toxicity was significantly higher in NDP (30%) versus DP 
(16%) (p=0.04). However, in a multivariate analysis including 
risk factors; age, baseline toxicity, IPSS, Comorbidity, 
number of needles, and prostate volume, the difference in 
late GU between the DP and NDP was not significant anymore 
(P=0.08). 
The influence of maximum displacement was not significant 
for late GI (p=0.71) nor GU (p=0.49) toxicity. 
The number of displacements was also not significantly 
associated with both late GI (p=0.73) and GU (p=0.60) 
toxicity. 
Conclusions: Corrected displacement during the 4 fractions 
regimen of HDR monotherapy did not lead to an increase in 
acute nor late GI and GU toxicity confirming the feasibility of 
our correction protocol to ensure a safe HDR treatment 
regimen. 
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Purpose/Objective: To evaluate the efficacy of CT-guided 
radioactive seed implantation for locally recurrent rectal 
cancer (LRRC) , and analyze the associated prognostic 
factors. 
Materials and Methods: From September 2003 to October 
2014, 97 patients with locally recurrent rectal cancer 
received 125I seeds implantation under CT guidance in our 
center. Each patient underwent three-dimentional treatment 
planning pre-implantation and dosimetric verification post-
implantation. The range of activity of seed was from 0.40 to 
0.8 mCi, and the range of seeds number was from 18 to 137. 
The range of D90 was from 75.91 to 165.27 Gy. Overall 
survival of the patients was calculated and prognostic factors 
were evaluated. 
Results: The follow-up rate was 93.5%, the median follow-up 
time was 15.7 months (4.2 ~ 98.1 months). The response rate 
of pain relief was 95.2%. The overall response rate was 
51.6%, in which complete response rate was16.1% and partial 
response rate was 35.5%. The 1, 2 and 3 year local control 
rates were 32.3%, 11.3% and 11.3%, respectively. The median 
local control time was 8.0 month. The 1, 2 and 3 year 
survival rates were 67.6%, 36.0%and 7.5%, respectively. The 
median overall survival time was 21.5 months. Analysis using 
the Cox proportional hazards model suggested that patients 
with pre-sacral recurrence and patients who received a D90 
higher than 140 Gy may survive for a longer period. 
Conclusions: CT-guided radioactive seed implantation 
provides a safe and effective method to relieve pain, control 
local tumor growth and, to some extent, prolong the survival 
of patients with locally recurrent rectal cancer without 
additional complications. It is an alternative treatment 
option for locally recurrent rectal cancer, especially for 
those with previous pelvic radiation. Location of recurrent 
tumor and accumulated dose may be factors predictive of a 
favorable outcome for patients. These findings need to be 
validated by conducting further studies with larger cohorts.  
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Purpose/Objective: Surface mould brachytherapy (SMB) is a 
century old technique which can be used for various sites 
such as skin, nose, ear and hard palate in the head and neck 
region. There is scarcity of data on high dose rate (HDR) SMB. 
Aim of this study is to evaluate the outcomes of patients 
treated with SMB technique. 
Materials and Methods: Patients with malignant localized 
early T1 or T2, node negative lesions in the head and neck 
region treated with SMB during 2008-2013 were considered. 
Individualized mould was prepared for all patients. Three 
dimensional CT based planning was carried out with the 
mould in situ using the Plato planning system (Nucletron). 
The median number of catheters was 5 (Range 3-7). 
Treatment was delivered using HDR 192 Ir source to a dose 
ranging from 39 to 52.5 Gy (mean 49 Gy) with 350cGy per 
fraction, using bid regimen. Median number of catheters used 
were 5 (range 3 to 7). For the present analysis the data was 
extracted from a prospective brachytherapy database as well 
as from patient charts. The data was analysed using SPSS 
software (V18). Survival analysis was done using Kaplan Meier 
method. 
Results: Thirty one patients were treated with SMB. The 
median age at presentation was 53 years (range 25-82 years). 
Most of the patients were males (n=24). The most common 
site was hard palate in 14 (45%), followed by nose in 7 
(22.5%), soft palate in 5 (16%), tonsil in 2 (6.5%), skin over 
face in 2 (6.5%) and pinna 1 (3.5%). The histology was 
squamous carcinoma in 27 patients, while the rest were basal 
cell carcinoma. The median tumor size was 2 cm. Treatment 
was given in the primary setting in 29 and recurrent setting in 
2 patients. Twenty three patients received the SMB as 
definitive, radical treatment while in 8 it was used as boost 
after external beam radiotherapy. Acute skin toxicity was 
seen in 17 patients of which 10 were grade II reactions. Acute 
mucosal reactions were seen in 19 with grade II in 10 and 
grade III in 1. Median follow up was 29 months (range 4 to 78 
months). Eight patients had recurrent disease (4 primary, 3 
isolated nodal recurrences and 1 primary and nodal 
recurrence). Two patients had died at 4 months and 14 
months. Three year DFS was 70% and 3 year overall survival 
was 91%. Grade 1 mucosal atrophy was seen in 22. Grade 1 
xerostomia was seen in 6 and grade II for 1 patient (all of 
them had received external radiotherapy). On long term 
follow up osteo- necrosis was seen for 2 of which 1 
recurrence had at the primary site. Skin hypopigmentation 
was seen in 3 while telangiectasia was seen in 9 patients. 
Conclusions: Surface mould brachytherapy results in 
acceptable locoregional control rates and good overall 
survival with excellent organ and function preservation.  
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Purpose/Objective 
Background:  
Bladder preservation combining surgery and radiotherapy 
could maintain quality of life without compromising tumor 
control in selected patients with bladder carcinoma. Several 
reports confirm good results. Prognosis of patients presented 
with recurrence after primary treatment with this regimen is 
not well known. 
We report the long term results of treated recurrences after 
bladder preservation treatment with brachytherapy. 
Materials and Methods: Between 1989 and 2011, 192 
selected patients with muscle-invasive bladder cancer were 
treated with a combined regimen of preoperative external 
radiotherapy, and subsequent surgical exploration with or 
without partial cystectomy and interstitial brachytherapy. 
Data of patients presenting with local recurrence after this 
regimen were retrospectively collected. The primary end 
points were local recurrence-free survival (LRFS) and overall 
survival (OS) (after the treatment of recurrence). 
Complications of the secondary treatment were reported. 
Results: The median follow-up after primary treatment was 
105 months (6-212 months). In 40/192 (20.8%) patients a 
local recurrence was detected. Four patients were excluded 
because of lack of data.  
Treatment of the local recurrence was performed in 28/36 
(78%) patients. For 18 patients a salvage cystectomy was 
performed; 10 patients were treated with transurethral 
resection followed by intravesical BCG. In 4 patients 
cystectomy procedures were discontinued. 
The local recurrence was muscle invasive in 19 patients; 
mostly treated by salvage cystectomy (14/19). The LRFS after 
the treatment of recurrence was 70% and 55% after 2 and 5 
years, respectively. The OS 2 and 5 years after treatment was 
71% and 34%, respectively. The LRFS of the 18 patients 
treated with salvage cystectomy 71% after 2 years as well 5 
years and the OS was 67% and 36% after 2 and 5 years, 
respectively. 
In 11/18 (61%) patients treated with cystectomy, surgical 
complications were reported, 6/11 patients with Clavien 
Dindo complications grade ≥ 3.  
Conclusions: The LRFS of patients treated for local 
recurrence after bladder-sparing regimen using 
brachytherapy offers good long-term oncological outcome. 
Salvage cystectomy gave the best long term local control, 
unfortunately with more surgical complications.  
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Purpose/Objective: Interstitial multicatheter brachytherapy 
is the most frequently used technique of partial breast 
irradiation, and could be used to deliver surgical bed boost 
and moreover exclusively accelerated partial breast 
irradiation (APBI). Our purpose is to evaluate our clinical 
results using both options of high dose rate (HDR) 
brachytherapy, in a risk adapted way.  
Materials and Methods: Between 1999 and 2014, 276 breast 
cancer patients has been treated with brachytherapy in our 
institution, with a mean follow-up of 65 months. It has been 
used as a boost combined with external beam radiotherapy 
(EBRT) in 125 patients with a median dose of 8 Gy in 
tumorectomy bed added to conventional doses of EBRT (50 
Gy). In the others 151 patients it has been delivered as 
exclusive APBI, with a dose of 32 Gy separated in 8 fractions 
of 4 Gy. ASTRO and GEC-ESTRO APBI recommendations has 
been registered for every patient.  
Results: The mean age at diagnosis was 61.67 years (range: 
24-92), 80.4% presented a postmenopausal status, in 82% 
tumor size was < 2 cm, 47 % grade I, 35% grade II and 13% 
grade III. Using APBI GEC-ESTRO recommendations, patients 
were classified as low risk in 41%, intermediate risk 21% and 
high risk 38%. For the ASTRO criteria, patients were classified 
as suitable 31%, cautionary 37% and unsuitable 32%. Most 
intermediate and high risk patients treated with APBI were 
elder than 70 years or they lived far from our institution. 
With a mean follow-up of 65 months (range: 4-179), actuarial 
local disease free survival was 98.1% at 5 years and 94.1% at 
10 years. Actuarial cause specific survival was 96.8% at 5 
years and 94.2% at 10 years. Five years and 10 years actuarial 
overall survival were 90.1% and 85.7% respectively.  
For the whole group, the best risk fit was obtained using 
GEC-ESTRO recommendations for APBI, with a local disease 
free survival at 5 and 10 years of 100% for those patients with 
low risk of recurrence. 
Conclusions: HDR risk adapted brachytherapy represents a 
good approach in breast cancer conservative treatment in 
terms of local control and survival. GEC-ESTRO 
recommendations has demonstrated to be a good tool to 
select patients treatment option. 
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Purpose/Objective: To investigate the outcome after PBI 
with 192Ir interstitial HDR brachytherapy in patients with early 
breast cancer. 
Materials and Methods: From August 2003 to May 2014 260 
patients aged 42-85 years (median 67) were enrolled. There 
were 237 infiltrating tumors and 23 DCIS (median tumor size 
9 mm, range 1.25-28) ER and PgR were positive in 236 and 
210 cases respectively. Axillary nodes were negative in 257 
patients; 3 patients had the sentinel positive node, 1 with 
micrometastasis. 29 patients received adjuvant 
chemotherapy, 221 hormonal therapy. Treatment schedule 
was 4 Gy twice a day for 4 days, up to a total dose of 32 Gy 
with an interval between fractions of at least 6 hours. 
Survival was analyzed by Kaplan-Meier estimator. Cosmetic 
results were evaluated, using the Harvard criteria, by 
radiation oncologists and patients, Cohen's k-test of inter-
rater agreement (k-value ranging from 0 to 1) estimated 
concordance between patients and physicians.  
Results: Median follow-up was 74 months (range 2-128). Four 
local relapses (1.5%) were observed 12, 24, 48, 96 months 
after PBI. One regional relapse was observed in the 
